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1. Bulgaria
1.1 An example of strategic 
cooperation: Setting up a working 
group to discuss a platform for 
change in drug policy in Bulgaria
Bulgaria, Sofia, 2012
Action at national level
Policy makers: Implementation of dialogue 
mechanisms
CSOs: Building a coalition and proposing 
actual changes in national drug policy 
legislation
Background
Drug policy decisions in Bulgaria are taken by the 
National Drug Council. This is an inter-ministerial 
body chaired by the Minister of Health and 
including members from ten ministries and eleven 
state agencies. It  operates in the area of national 
security and social issues. The Council adopts the 
national strategies and programs in the drugs area, 
coordinates international obligations and relations 
and has the mandate to propose legislation changes 
related to drugs. In principle, the Council does not 
collaborate with civil society structures and has no 
formal mechanisms to assess civil society experiences 
or opinions when taking decisions, proposing 
legislation changes or adopting official documents. 
There have been few isolated cases of inviting civil 
society representatives to the sessions of the Council. 
In 2012 a group of non-governmental organizations 
and citizens organized themselves and agreed upon 
common points for change in the drug policy of the 
country. They developed a Platform for change: a 
document with motivated suggestions for grounding 
reforms in the philosophy of the Bulgarian drug 
policy. Among these were: the revision of the drug 
possession penalties, revision of the  cannabis policy, 
introduction of alternative penalties for PWUD who 
commit criminal offenses, reduction of imprisonment 
rates, strengthening of the civil society’s and experts’ 
participation in the decision-making process, 
improvement of funding schemes and introduction of 
effective evaluation mechanisms. 
The platform was submitted to the National Drug 
Council and following that the Minister of Health 
established a working group to discuss the platform 
propositions. The working group involved government 
officials from the Council and civil society 
representatives.  
Objectives and expectations  
The CSOs coalition had two objectives with this 
act: to initiate a dialogue with policy makers and 
to create a forum to discuss their concerns; and to 
initiate a process of concrete changes in specified 
areas. 
The working group had the objective to analyse 
the Platform and report back to the National Drug 
Council. 
Achievements 
The working group had several meetings and drafted 
a report. Consensus was achieved for two out of 
five points (improvement of the funding schemes 
for treatment and rehabilitation and introduction of 
effective evaluation mechanisms), although these 
were not followed by concrete steps. One point 
was partially supported (introduction of alternative 
penalties for PWUD who commit criminal offenses) 
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and it was proposed to the Council to submit a further 
proposal in this regard to the Ministry of Justice.  Two 
of the points did not reach a consensus: the revision 
of drug possession penalties and the revision of the 
cannabis policy. 
The main achievement of  this working group was to 
be the first example of a formally established dialogue 
forum between the policy makers and CSOs. It also 
made possible further discussions for  part of these 
points. 
Challenges
The main challenges were related to the poor 
advocacy experience of CSOs at that time and their 
attempt to address too many basic issues at the 
same time. Nevertheless, the missing abilities of policy 
makers to conduct a dialogue with civil society and 
the lack of formally established procedures for such 
were also important difficulties in the process. 
Developments and evolution 
The only point which advanced was related to 
cannabis policy. Although there has been no change 
in the Bulgarian legislation in regard to cannabis, the 
dialogue on this topic was intensified in the next years 
and the Council organized additional research on the 
use of medical cannabis. 
Drug possession and other drug-related penalties 
remained unchanged. Funding and evaluation 
mechanisms also did not improve.   
Lessons learned
CSOs should be prepared to initiate policy changes 
with good knowledge of the decision making 
mechanisms and should address problems separately 
with a well-prepared strategy and a realistic 
timeframe.
Policy makers should be prepared to discuss their 
decisions with civil society and should have diverse 
mechanisms to research opinions and experiences 
from the ground. 
1.2. An example of media 
advocacy actions: Advocacy for 
medical cannabis in Bulgaria
Bulgaria, 2012 -2015
Action on National level
Actions by CSOs:  Advocacy actions - 
participating in decision making process.
Stakeholders and parties involved: CSO’s: 
Promena and Restart and National Drug Council 
Background
Bulgarian drug laws do not allow any type of medical 
cannabis treatment, nor do they distinguish between 
possession of medical cannabis by patients and 
possession for recreational use. This happens because 
the cannabis/THC is classified as a high risk drug 
without application in medicine. The classification is 
the responsibility of the Bulgarian Minister of health. He 
is the chair of the National Drug Council. In practice 
all drug policies depend on the Council. Its sessions 
are being held behind closed doors. A specific 
decision of the Council is needed for external people 
or organizations, including CSOs, to be present.
Several CSOs were motivated to change the policies 
about medical cannabis. In May 2012 the CSO 
sector developed a “Policy Change Platform for 
Psychoactive Substances in Bulgaria”. One of the 
2. Methods
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1demanded changes in drug policies and laws relates 
to the classifications of drugs. In respect to cannabis, 
there was the aim to classify it as “a drug with 
application in medicine”. This has been introduced 
to the Council. At the Council’s meeting in 2012, it 
was decided to set up an inter-ministerial working 
group to discuss these proposals. During the working 
group sessions, the CSOs made more detailed 
proposals. In 2013 the working group issued a report 
which proposed to include cannabis/THC on the list 
of drugs with application in medicine. 
Meanwhile, in April 2013, Marin Kalchev, a medical 
user with multiple sclerosis was caught with cannabis 
and sent to court. The CSOs supported him with a 
lawyer and a massive media campaign. For several 
months, the media produced a number of interviews 
and articles on the issue. In March 2014, an acquittal 
was issued to Marin at first instance. 
As a result of this case and the media attention, the 
National Centre for Addictions was commissioned 
to draw up a single opinion covering all aspects of 
the medical cannabis. The same went out in 2014 
and, although it describes the medical application 
of cannabis/THC/CBD in number of countries for 
different illnesses, it was extremely negative to the 
re-classification of cannabis.
Following this opinion, the National Drug Council 
held an extraordinary session. Nothing was decided, 
but at least CSOs’ experts were heard. In 2015, the 
Council decided to carry out an analysis of the 
published studies regarding the appropriateness and 
necessity of the use of cannabis and its derivatives 
for medical purposes, considering also the regulatory 
practice and control in other EU countries. The 
CSOs were not informed, but through access to 
information procedure it was possible to find that two 
studies had been ordered: one to the Bulgarian Drug 
Agency ,on regulatory practices and control, and 
another  to the National Center for Public Health and 
Analyses, on the medical application of cannabis. 
In November 2015, during a closed door session, 
the National Drug Council decided not to reclassify 
cannabis. Instead of the two reports commissioned 
in February, which were not discussed, well selected 
conservative health experts were summoned to 
express their opinions. The report from the National 
Center for Public Health and Analyses had not 
been  adopted, and although it had been  sent to 
the Council it was  not published on the Council’s 
website. This was done only after the CSOs started 
to ask about it. The report is quite objective and 
balanced, and shows well-researched medical 
applications of cannabis/THC. Later, the report 
got published on paper, in collaboration with the 
National Center for Public Health and Analyses 
and some of the CSOs. The  research done by the 
Bulgarian Drug Agency appeared after a year, and 
again, following CSO’s request. 
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Objectives and expectations
The objectives of this action were: to open the 
National Drug Council for public and experts’ 
participation; to make medical cannabis discussion 
visible in the society; and to change the policies in 
order to allow medical application of cannabis. With 
that, our expectation was to: switch mass audience 
perception on the topic, due to revealed personal 
stories of medical users and expert opinions; change 
policies; and to fight the strong opposition from 
conservative influencers, experts and authorities.
Achievements
• Better understanding of the mass audience; 
• The participation of CSOs in several sessions 
of the National Drug Council and the working 
group; 
• A court decision on first instance respecting the 
right of medical use, although the law prohibits 
it; 
• Published positive opinions of the working group;
• To have published the National Center for 
Public Health and Analyses’  research on the 
medical application of cannabis, showing such 
application is strongly based on science.
Challenges
• To overcome the conservative opinions, 
especially if they are expressed by officials and 
politicians; 
• To convince society that medical cannabis does 
not open the doors for the legal recreational use 
if policies are applied correctly.
Developments and evolution
After the campaign for medical cannabis the 
CSOs are not invited at the National Drug Council’s 
sessions. Even the agenda and minutes are no 
longer published online. 
Lessons learned
• Showing a personal story of a cannabis medical 
user was a good strategy for accessing mass 
media;
• Under media pressure, authorities are getting 
open at least for discussion with CSOs; 
• It is hard to follow and influence drug policies 
if the National Drug Council is working behind 
closed doors; 
• Access to information procedure is a powerful 
tool to get information and to put pressure on  
the Council.
csidp
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2.1. An example of CSO 
leadership: Supporting the 
implementation of supervised 
injecting facilities in Ireland
Ana Liffey is a CSO based in Dublin, Ireland, 
working primarily with people who use drugs, many 
of whom inject drugs. In 2012, the organisation 
recognised the need for supervised injecting 
facilities in Dublin in its strategic plan and pledged 
to work towards their implementation. In doing 
so, the organisation recognised that a significant 
barrier to implementation would be legal. First, 
the organisation set about identifying the key 
legal issues by conducting a detailed analysis of 
both domestic and international law in relation to 
supervised consumption. This piece of work was 
finished in late 2013, and concluded that legislative 
change would be required for supervised injecting 
facilities to operate on a stable legal footing in 
Ireland. From here, the organisation sought the 
support of the Voluntary Assistance Scheme of the 
Bar of Ireland. They agreed to support, and put 
together a legislative drafting committee - a group 
of barristers who generously gave their time pro 
bono to work with the organisation. The output, in 
early 2015, was a legal opinion from the committee 
along with a draft legislation which, if introduced, 
would establish a legal framework within which 
supervised injecting facilities could operate in 
Ireland. 
This gave the organisation a powerful tool: instead 
of merely calling on State actors to address the 
issue, Ana Liffey could provide a detailed analysis 
which could assist politicians and civil servants in 
their work on the topic. The materials were passed 
over to the newly appointed Minister of State with 
responsibility for the National Drugs Strategy, and he 
prioritised it during his time in office, culminating in 
a cabinet decision (in December 2015) to legislate 
for supervised injecting facilities Over the next year, 
State actors carried out their work putting into 
action the cabinet’s decision. Ana Liffey provided 
input to the legislative process through advocacy 
actions and by providing input to legislators and civil 
servants.
The result of this process was that the Oireachtas 
(Irish Parliament) passed the Misuse of Drugs 
(Supervised Injecting Facilities) Act 2017, which was 
signed into law by the President of Ireland in May 
2017. Ireland now has a legal framework under 
which supervised injecting facilities can legally 
operate. A tender process is underway to identify 
a service provider for a pilot service. The service’s 
establishment is also an action in the current 
National Drugs Strategy.
This is a good example of a CSO conducting 
detailed and focused work to help move a 
particular policy issue on. It is also a good example 
of state actors being open to and supportive of 
CSO involvement in bringing a policy issue from 
conception to realisation. 
2.2. An example of a coalition: 
CityWide and Decriminalisation  
in Ireland
As part of their work through their networks, CityWide 
identified the damage that criminalisation of 
simple possession was having in Irish communities 
and facilitated discussions in their groups, raising 
2. Ireland 
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awareness of the issue. Through a combination 
of lived experience and independent evidence, 
these community networks have coalesced to 
support an approach which no longer deals with 
people who use drugs as criminals.  This debate led 
to a recommendation in the 2012 Citywide Policy 
Document  for them to participate in an open 
debate on decriminalisation.
In May 2013 Citywide organised a national 
conference - “Criminalising Addiction – is there 
another way?”. This was done with expert speakers 
from the Health Research Board and from the 
UK, who presented an overview of the available 
evidence. This was the first time that all stakeholders 
in Irish drugs policy across statutory, community and 
voluntary sectors came together to discuss issues 
around alternatives to criminalisation for drug use. 
There was a good uptake and engagement from 
both state and CSO actors, the conference being a 
good setting for dialogue on this crucial drug policy 
issue.
Follow up work to the seminar involved two main 
elements: developing CityWide’s own knowledge of 
the evidence base through international contacts 
and research and promoting discussion and debate 
on the issues through ongoing activities, including 
local community meetings, national family support 
meetings, inputs to seminars and drug awareness 
events. CityWide also linked their work to political 
processes, meeting with politicians of all parties 
and groupings to brief them on the issues and has 
continued to provide information to them on an 
ongoing basis. CityWide’s work on this issue has 
been far reaching and has contributed greatly to 
the national debate. Some of the advocacy and 
research activities undertaken comprise of lobbying 
and participating in fora at national level, including:
• Presenting on alternatives to criminalisation 
at a think-tank organised by the then Minister, 
Aodhán O’Ríordáin, in July 2015;
• Advocating before a Joint Parliamentary 
Committee which ultimately “strongly 
recommend[ed] the introduction of a harm 
reducing and rehabilitative approach, whereby 
the possession of a small amount of illegal drugs 
for personal use, could be dealt with by way of 
civil/administrative response rather than via the 
criminal justice route” in July 2015;
• Presenting at a parliamentary briefing held by 
Senator Lynne Ruane in May 2017;
• Commissioning Red C to look at attitudes 
towards drug use and drug users in Ireland 1; 
• Developing a dedicated web resource2  
concerning decriminalisation in the Irish context;
• Being a CSO representative on the Working 
Group tasked with developing the National 
Drugs Strategy 2017-2025. This group has been 
established under the new strategy to consider 
decriminalisation as a policy and to make 
recommendations to the Minister which are 
expected in late 2018 / early 2019.   
The result of this activity is that Ireland has a 
strong and coherent CSO voice in the national 
conversation around decriminalisation as a policy 
choice. This work has contributed to the current 
position in Ireland, whereby a working group has 
been set up under the National Drugs Strategy with 
a view to making policy recommendations to the 
Minister with responsibility for the National Strategy 
by early 2019.
1 More info at: http:\www.citywide.ie\news\2016\12\07\half-of-population-in-favour-of-decriminalisation-citywide-red-c-poll\
 2 Available at: https://www.citywide.ie/decriminalisation/
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2.3 An example of a CSO active 
on the national level: The National 
Family Support Network (NFSN) in 
Ireland
As part of their work, NFSN had long identified a 
significant problem with drug related intimidation 
among people they worked with. In essence, 
people who use drugs and family members can be 
intimidated by drug dealers to repay drug debts. 
Having conducted research into the phenomenon 
in 2009, with family support facilitators nationwide, 
NFSN identified that forms of intimidation can 
include threats, physical violence, damage to 
the family home / property and sexual violence. 
Some people try to repay these debts through 
cash payment or involvement in illegal activity. The 
experience of intimidation can be very frightening 
and can pose a serious risk to the individuals 
involved and their loved ones. There can also be 
a fear of contacting statutory services such as the 
police for help, and uncertainty over what such a 
process could entail.
Recognising that the issue required a tailored 
response, the NSFN worked with An Garda Siochána 
and other stakeholders to develop the Drug Related 
Intimidation Reporting Programme. This was a 
good example of a statutory agency (An Garda 
Siochána) and a CSO (NFSN) working in partnership 
to develop a response to a cross-cutting policy 
challenge. Under this project, there is a nominated 
officer at management level in the force in each 
station who is tasked with drug related intimidation. 
People suffering from drug related intimidation 
can contact that person in confidence, including 
meeting them at a location outside the police 
station and with the officer not in uniform, if needed. 
At an initial meeting, the police will:
• Provide practical safety information;
• Provide advice in relation to particular threats or 
instances of intimidation;
• Provide information on appropriate drug 
support services for the individual in the family 
who is accruing drug debts;
• Outline how to make a formal complaint, 
what is involved, what happens after and 
possible outcomes.To further support the person 
experiencing intimidation, a training was given 
to support workers in a variety of organisations 
to enable them to: 
• Listen to a person’s experience of intimidation;
• Support them to think through their decision 
in relation to payment, non-payment and/or 
seeking help from the police;
• Provide information on the Drug Related 
Intimidation Reporting Programme;
• Help to arrange a meeting with the nominated 
police officer for the area.
In addition, NFSN developed a policy to 
accompany the programme and allow services to 
embed the knowledge and use of the programme 
into the internal protocols and procedures of the 
individual project. This allowed to build capacity 
and to raise awareness among other CSOs and 
community actors.
The project has been operational since 2013, and 
is now embedded as a policy approach in Ireland. 
The current national drugs strategy ‘Reducing Harm, 
Supporting Recovery (2017-2025)’ mandates activity 
to strengthen its effectiveness by conducting an 
evaluation of the programme and taking steps 
to raise awareness of its use. It also notes the 
importance of the partnership approach between 
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state and CSO in developing this policy initiative:
“Recognising the harm caused by drug-related 
debt intimidation, An Garda Síochána will carry 
out an evaluation of the Drug-Related Intimidation 
Reporting Programme to strengthen its effectiveness 
and to identify further opportunities to build on 
that work through Community Safety Fora and the 
creation of linkages with community policing and 
the asset profiling programme. The National Family 
Support Network, who have worked with An Garda 
Síochána to build support for this programme, 
will also carry out their own evaluation from the 
perspective of their network. These reviews will further 
inform development of the reporting programme by 
An Garda Síochána and the National Family Support 
Network. The depth of experience and knowledge 
built up by the community sector in responding to 
this situation will be an immensely valuable resource 
to this strategy.” 3
 
csidp
 3 National Drugs Strategy, p.65
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3.1 An example of implementing 
involvement mechanisms: The 
Regional Working Group on the 
Piemonte Harm Reduction Basic 
Levels of Care Protocol in Italy
Italy, Piemonte Region, 2017
Action at regional level
Policy makers: Implementation of partnership 
mechanisms
CSOs: participating in a decision making 
process dealing with regional drug services 
system and PWUD rights to health and social 
welfare
Background
In Italy, drug treatments and services are guaranteed 
by Regional Public Health Systems (Law n.309/1990); 
services can be provided both by the public sector 
directly and by non-profit organizations, which are 
financed by the public health budget. The central 
Government establishes the annual national health 
budget to be split among the Regions on the basis 
of a number of  criteria. This is a yearly political 
negotiation between the State and Regions and the 
LEA –Livelli Essenziali di Assistenza – on the basic levels 
of care which the Regions must comply with. 
In the field of drug services, treatments such as 
Opiate Substitution Treatment, Anti-Retroviral 
Treatment, and psychosocial assistance) are 
included in the LEA. They are free of charge, open 
to all (including illegal migrants), and implemented 
in all Regions. Until 2016, harm reduction services not 
directly related to treatment, such as Needle and 
Syringe Exchange Programs,  Take Home naloxone, 
outreach interventions, and drop-in centres were 
excluded from the LEA, due to abstinence-oriented 
and prohibitionist national drug policies. This meant 
that it was  not mandatory to implement them. As 
a result, harm reduction interventions are carried-
out in 12 Regions out of 20, but only in 6 regions this 
happens in a stable way. Six Regions have no harm 
reduction interventions at all and 2 never provided 
information. Among the “harm reduction virtuous” 
Regions, there are no homogeneous harm reduction 
guidelines/standards, nor common monitoring 
systems. PWUDs right to health is not ensured. Since 
2017, also thanks to advocacy actions by CSOs and 
professionals, harm reduction was included in the 
LEA by the Health Ministry. Regions have now the 
task to write a detailed description of services to 
be delivered, guidelines and minimum standards. 
Piemonte is one of the “harm reduction virtuous 
regions”, where these services have been provided 
since mid- 90s. It was the first Region to write its harm 
reduction LEA Protocol, thanks to a Regional Working 
Group established by the Health Department, 
including public and private sector professionals, 
CSO experts involved in harm reduction, and PWUD 
organizations.
Previous experiences
CSO participation has been possible thanks to a 
number of reasons that characterize the Piemonte 
context:
• Long term experiences, since early 90s, of 
collaboration and synergy between professionals 
of public and Third sectors;  
• A high number of professionals of all sectors  
who assumed a “political responsibility” and an 
advocacy perspective;
3. Italy 
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• A long term collaboration with one of the most 
significant PWUD organization in Italy, involved 
in the planning and implementation of the harm 
reduction system  (Isola di Arran);
• The involvement, since 1999, of an independent 
network of professionals, peer educators, 
researchers and activists involved in harm 
reduction and low threshold services (COBS); 
• The previous, successful experience of a 
Regional Working Group established by the 
Health Department in 2007-2008 with the task 
of writing a Regional harm reduction Plan and 
other duties, including CSOs, professionals and a 
PWUD organization.
Objectives and expectations
The Regional working group on harm reduction LEA 
Protocol had the task to: 
• Decide which HR services should be included 
in the LEA on the basis of the local context 
(patterns of use, PWUD needs, public health 
goals), scientific evidence, assessment of 
previous experiences, human rights and right to 
health perspective; 
• Identify supporting references and evidences; 
• Establish minimum standards of the services. 
The harm reduction LEA document will be discussed 
by the Health Department and by the Directors 
of Public Drug Departments. Once approved, 
eventually after a negotiation, the protocol will be 
cogent throughout the Region, also in those areas 
where harm reduction has not been implemented 
until now. This is, of course, the first positive expected 
change.
Achievements 
LEA, in general, is a political-technical issue in the 
Italian national and regional health system. It is 
the concrete way to make the Right to Health 
enforceable, because they guarantee access to 
care. To implement harm reduction LEA means to 
guarantee for all PWUD in the Region the right to 
protect their lives and to promote their health and 
wellbeing. This is more than “some new services” 
only: it is a different perspective and a different drug 
policy.  
Harm reduction LEA is also a scientific and 
operational matter, as it leads to changes in the 
organization of the drug service system. CSOs 
contributed their competence in providing, 
monitoring, evaluating HR services and in carrying 
research activities. The working group is an excellent 
context to share knowledge and an opportunity 
to improve and “validate” the role of CSOs in drug 
policy at regional level.
Challenges
This process will encounter three challenges: 
• Upholding the principles of both evidence and 
human rights  in the decision making process on 
drug policies, beyond ideological approaches; 
they will have to be supported, defended an 
negotiated; 
• A financial challenge is that even if harm 
reeuction LEA must be delivered and 
guaranteed, the regional budget might not be 
sufficient to cover all expenses. CSOs will need 
to monitor harm reduction investments; 
• Implementing drug checking within the frame 
of outreach interventions in natural settings of 
use, even if they are still experimental in Italy, 
and delivering harm reduction services in prisons 
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(today no Syringe Exchange, nor condom 
and Naloxone delivery are authorized). Their 
introduction might lead to conflict.
Developments and evolution 
The Regional working group has concluded its 
activities in January 2018. Being the first one at 
national level, the harm reduction LEA Protocol by 
Regione Piemonte is going to become a reference 
point for other Regions, also thanks to the working 
group advocacy initiative.
All participants have agreed on the proposal to 
make the working group a stable body, with the 
task of monitoring, evaluating and innovating harm 
reduction regional policy. The group might promote 
an experimental protocol aimed at opening a 
Drug consumption room in Torino. Italy has no 
drug consumption rooms yet. These facilities are 
mentioned in the working group document, but it 
has not been possible to include them as LEA. In a 
note, the Group recommended an experimental 
protocol at regional level, based on the evidence of 
30 years of experience in Europe. 
Lessons learned 
CSOs role in drug policy processes can be more 
effective and be improved if:
• Professionals of public and Third Sector are 
committed in drug policy and not just to a 
“technical role” ;
• Independent networking  is a strong point, 
bringing different stakeholders to share the 
respective competences and objectives and 
to build alliances, facilitating exchanges, 
transparency and open debate;
• PWUD are involved and recognized by all the 
stakeholders and by the public sector;
• At the basis of each drug policy process there 
is a strong link between evidence (scientific 
discourse) and civil / human / citizen rights 
(political discourse), and the coherence and 
balance between these two discourses is an 
integral part of the process goals.
3.2 An example of consultation: 
CS-Government Dialogue Session 
on the Italian position at UNGASS 
2016
Italy, 2015-2016
Action at national level
Policy makers: Implementation of dialogue 
mechanisms
CSOs initiative: Implementation of dialogue 
mechanisms; Public awareness raising
Background
From 2006 to 2011, the Italian right-wing government 
has been radically  oriented towards a war on drugs 
–. This had hard consequences not only for the  
national drug policy, with the reform of the drug law 
in an hyper-prohibitionist perspective and the ban 
of harm reduction, but also at international level. 
From 2005 onwards, the European Union (EU) and 
the Horizontal Drugs Group began to prepare for the 
10th anniversary of the Political Declaration adopted 
during the UNGASS in 1998, in view of the CND High 
Level Meeting in 2009.  The EU called on the CND 
to have an evaluation of the achievement of the 
1998 UNGASS objectives, insisting that an open 
debate on the assessment was necessary before 
15
csidpGood  Practice Collection
any new political declaration could be negotiated. 
The negotiation went well initially, but then Italy and 
Sweden opposed to the concept of harm reduction, 
and to using the term in official documents. The Italian 
government went furthest and ultimately broke the 
EU consensus, cutting out the negotiation strategy 
that had endured for several months. As a result, 
the High Level Meeting ended with an implosion of 
EU cooperation. Berlusconi’s minister responsible for 
drugs, Mr. Giovanardi, gave a statement entirely at 
odds with the European position4. 
Previous experiences
From 2006 to 2011, Italian harm reduction and drug 
policy reform NGOs  organized many campaigns 
against Berlusconi’s  government drug policy, 
focused on both drug law reform and on harm 
reduction development and support. Some of 
these were successful. The repressive law n. 49/06, 
for instance,  was abrogated in 2014 by the High  
Court and harm reduction interventions became 
Basic levels  of assistance in 2016. In 2010,  Italian 
NGOs sent a letter to the Horizontal Drugs Group 
to declare the opposition of the majority of CSOs 
to the government position, and to condemn the 
ideological and repressive Italian drug policy. After 
2011, the following centre left-wing governments 
have showed very little regard for drug issues in 
general. The network for drug policy reform Cartello 
di Genova put the UNGASS 2016 process in its political 
agenda at its national Conferences in 2014 and 
2015. In 2015, in view of the general Assembly, an 
Open letter5 to the Prime minister Renzi was signed 
by the majority of CSOs. Among others, the letter 
asked for: a clear discontinuity with the 2009 anti-
EU position; the support of a common European 
position  in New York  assembly; the evaluation of 
global drug policy outcomes through an independent 
expert advisory group; and a specific focus on harm 
reduction and human rights. An intensive exchange 
and collaboration with international networks 
(such as IDPC, UNGASS Asks, Budapest Groups 
Recommendations, and CSFD Recommendations) 
made it possible to Italian NGOs to develop their 
proposals in a more effective way (. 
Objectives and expectations
In  March 4th 2016,  the Cartello di Genova, thanks 
to the leading action  of Forum Droghe and 
Associazione Luca Coscioni, organized a Dialogue 
Session with the Italian government. The dialogue 
counted with the Ministries Council, in particular 
with the Justice Minister,  delegate to represent Italy 
at UNGASS in New York. The Dialogue has been 
facilitated by the National Drug Agency6. Thanks to 
CSOs advocacy action,  a Parliamentary questioning 
was made a few days after the Dialogue session 
–- to have a clear and public feedback by the 
government on the Italian position in the New York 
assembly. The objectives of this Dialogue session were: 
• To inform and sensitize the government on Italian 
NGOs and international CS networks position and 
proposals about  UNGASS process and expected 
outcomes;
• To put pressure on the government to support 
a common EU position based on an “open and 
honest” debate, focused on harm reduction, 
human rights and  decriminalization perspective, 
and promoting an evaluation of the 1998  Political 
Declaration and Action Plan. 
• To create a new opportunity of Dialogue 
between SC and Policy makers, in order to give a 
voice to  SC organizations;
• To develop a new collaboration strategy  of 
dialogue with the (renewed) National Drug 
Agency over the breakup of 2009.
4 The full statement can be accessed here: http://www.ijdp.org/article/S0955-3959(14)00085-1/fulltext
5 The Open Letter can be seen here: https://ungass2016.fuoriluogo.it/2015/09/15/ungass-2016-avviare-il-confronto-in-italia/ 
6 More information on the dialogue can be found here: https://ungass2016.fuoriluogo.it/2016/02/24/ungass-confron        
to-col-governo-italiano/.
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Achievements 
The Dialogue Session was successful, counting with 
the participation of Ministries, institutional bodies’ 
delegates, and NGOs members. Italy has been 
one of the few countries in Europe where such a 
dialogue happened before the New York assembly. 
A discontinuity with the position oriented towards 
the war on drugs from 2009  was expressed, and the 
Minister of Justice clearly declared that the Italian 
position was aligned with the statement of the 
European Union. The Minister affirmed that:
“Since the entry into force of the drug conventions 
and the adoption of the Political Declaration in 2009, 
we have gained experience and new challenges 
have emerged. We thus need to adjust our 
domestic and international policies, strengthening 
projects that have proved to be effective and 
modifying those that have not, also in light of the 
Sustainable Development Goals”. Moreover he 
stressed Conventions’ flexibility as “to implement 
them in a more balanced, humane and effective 
way, assuring that our drug policies fully respect 
human rights and are truly health-oriented7(. A first 
step in a turnaround perspective has happened. 
Challenges
The fruitful experience of this Dialogue session may 
be a digression or, on the contrary, the first step 
towards a permanent process of dialogue CS-
government. Vienna 2019 will be the first test. Three 
variables are important here:
• Governmental drug policy: political elections will 
be held in March 2018; 
• National Drug Agency’s role: the current 
Direction is less willing than the 2016 one in 
playing such a political role; 
• CSOs and their capacity of advocacy action 
and networking on international issues: global 
drug policy seems not to be the first concern of 
Italian CS organizations, and so, it is necessary to 
raise their awareness.
Developments and evolution 
Vienna 2019 CND High Level Meeting is crucial to 
continue the open debate started in New York, as 
there is the risk of stepping back. It is crucial that the 
EU has a common and open position and that Italy 
plays a positive role in this direction. In view of CND 
session  in March 2018, Italian NGOs in favour of this 
perspective  are going to send to the government 
a set of Recommendations based  on the Civil 
Society Forum on Drugs statement8.  Once the new 
Government is established in March/April 2018, a 
new initiative will be planned according to the new 
context.
Lessons learned 
• National CSOs networking is a strong point. The 
2016 UNGASS action was facilitated by Cartello 
di Genova advocacy actions in 2014 and 2015 
and its capacity of building collaboration with 
the National Drugs Agency; 
• International CSOs networking is a strong 
point too. Recommendations and positions 
shared at international level are as effective 
as exchanging information and advocacy 
competencies;
• It is necessary that CSOs are  open minded  
towards international issues and are willing 
to come out of a certain “small-town” self-
referential mentality; the international scenario 
actually concerns local and national scenarios.  
  7 More information to be found here: https://ungass2016.fuoriluogo.it/2016/04/21/ungass-2016-intervento-orlando-879/
  8 The statement can be found here: https://ungass2016.fuoriluogo.it/2017/12/12/vienna-2019-le-raccomandazioni-della-societa-civile/
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3.3 A result of strategic planning: 
The inclusion of Harm Reduction 
as a prevention pillar in the new 
National AIDS Plan in Italy
Italy, 2016-2017
Action at national level
Policy makers: Implementation of consultation 
and dialogue mechanisms
CSOs initiative: Implementation of dialogue 
mechanisms; advocacy actions
Background and previous experiences
The Department of Antidrug Policies  of the Italian 
Premier’s office was created in 2008 by an ad-hoc 
decree as a “structure of support for the promotion, 
coordination and tuning of the government’s 
action in the area of anti-drug policies”. Since the 
beginning, being an integral part of the Premier’s 
office, it operated under the direction of the under-
secretaries who, in the first years and under right 
wing governments, contributed to the harshening 
of previous prohibitionist laws and the cancelation 
of progressive approaches in drug policies in 
favour of very conservative legislation and 
directives. Given such a prohibitionist approach, 
harm reduction strategies were banned for many 
years.The wording itself was eliminated by official 
documents: harm reduction strategies were 
redefined as “PPC, Prevenzione delle Patologie 
Correlate” –Prevention of Related Diseases 
strategies. The documents and recommendations 
of the Department of Antidrug Policies, which 
should be exclusively technical, were very often 
guided by ideological considerations. For the 
past ten years, interventions were limited to 
traditional harm reduction services (basically, 
needle exchange programs) and did not take 
into consideration the introduction of innovative 
approaches which had already proved to be 
effective in many other more progressive countries 
(such as drug consumption rooms, and drug 
checking, for instance). Harm reduction traditional 
services were reduced due to the changes in drug 
consumption modes, but new drug consumption 
habits were not given the necessary attention; no 
additional prevention measures were introduced 
to limit the new harms to the health of people using 
drugs.
Objectives and expectations
The working group set up in 2015 for the 
preparation of the new National AIDS Plan 
represented for civil society organizations an 
excellent opportunity to bring back harm reduction 
principles and approaches, as well as to introduce 
innovative approaches in the Italian drug policy 
agenda. The advisory bodies of the Ministry 
of Health on HIV/AIDS issues (Health Technical 
Committee – Sections L and M) included a large 
representation of CS organizations, which provided 
institutional colleagues from hospitals and scientific 
agencies with international guidelines and 
project reports which showed evidence for the 
effectiveness of harm reduction interventions. LILA 
Milano representatives, partners in this project, are 
members of the Health Technical Committee.
As a result of the long process and the discussions 
within the working group, the text of the new 
National AIDS Plan finally gives the right attention to 
harm reduction strategies.
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The document reports the following considerations:
…“Programs aimed at preventing HIV transmission 
are finalised to protect the individuals and 
their communities and are mainly focused on 
behavioural risk-reduction interventions. Given the 
complex nature of the epidemic, it is necessary 
to implement combination prevention programs 
that take into consideration specific factors for 
each context and include modules dedicated 
to reducing stigma and discrimination and to the 
defence of human rights. The relevance and full 
involvement of civil society and representatives of 
the most affected populations in all aspects are 
largely recognized by European and international 
Health Authorities.
• Harm Reduction and Risk Reduction 
interventions targeted to key populations: 
through the implementation of programs for free 
of charge needle distribution and exchange, 
distribution of male and female condoms; free 
of charge HIV testing services, opioid substitution 
therapy, interventions targeted to people 
affected by other STIs.
• Pharmacological interventions: prevention 
strategies based on the use of HIV antiretroviral 
therapies (PrEP, PEP,  TasP, therapies for the 
prevention of mother-to-child transmission).
• Structural interventions: aimed to reduce 
vulnerability to HIV associated to conditions 
such as poverty, gender inequalities, social 
discrimination and marginalization - with special 
reference to homo-transphobia and legal 
issues concerning sex work, drug use and illegal 
migration on the national territory. 
The above described interventions shall be 
integrated into public health programs with the 
purpose to revert the trend…” 
Challenges
The first of the many challenges of the innovative 
National AIDS Plan has been overcome in late 
2017, with its approval and adoption by part of the 
Conference of Regions. The main challenges now 
refer to getting the necessary commitment from 
the Regions in order to dedicate sufficient financial 
resources for the enforcement of the Plan, plus 
adequate human resources and other resources for 
its implementation.
Developments and evolution 
In the future months, the opening of a joint working 
group with the Regions, with the participation of 
civil society representatives, , could contemplate 
the following regarding the measures described 
in the National AIDS Plan with reference to harm 
reduction:
• Reintroduction of harm reduction terminology in 
all Regions, since some are still maintaining the 
old ban;
• Funding and homogeneous implementation of 
harm reduction programs in all Italian Regions;
• Increase the offer of HIV and hepatitis tests to 
people using drugs; 
• Introduction of new strategies that so far were 
not considered/allowed (Drug Checking, Drug 
consumption rooms);
• Adoption of homogeneous harm reduction LEAs 
in all Regions. 
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Lessons learned 
• National CSOs’ presence and collaboration in 
the working group for the definition of the new 
National AIDS Plan was extremely professional 
and effective, and succeeded in bypassing the 
deadlock in the relations with Italian institutions 
on the issue of drug policies; 
• The institutional representatives at the Ministry of 
Health demonstrated to be more prepared to 
take into consideration the evidence coming 
from European and International drug agencies 
and supported civil society instances for the 
reintroduction of harm reduction strategies 
in an official document. The new National 
AIDS Plan and its clear references to harm 
reduction interventions cannot be ignored by 
the Department of Antidrug Policies in the future 
definition of Italian drug policies; 
• Links with European CSOs contributed to the 
success of the process.
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4.1 An example of successful 
civil society involvement: The 
preparation of the process towards 
UNGASS 2016 in the Netherlands
Background
From the 19th to the 21st of December 2016, the 
General Assembly (GA) of the United Nations (UN) 
covered a Special Session aiming at reviewing the 
current drug policies of the moment, the development 
of the 2009 ‘Political Declaration and Plan of Action’ 
and considering alternative approaches. 
Parallel to the international development of this event, 
three contextual factors are crucial for understanding 
the preparation process of The Netherlands and the 
role that CSO’s played out in it:
• In the years previous to UNGASS 2016, the 
international discussion around drugs was 
shifting from a punitive approach towards a 
harm reduction framework which advocated for 
human rights and the decriminalization of drug 
use. Given this turn, The Netherlands considered 
what influence and expertise it could bring into 
the discussion, as harm reduction strategies have 
been a central feature of its drug policy already 
for decades. 
• Despite the fact that the European Union has no 
vote in the GA and that drug policy is a national 
competence of the state members, there’s 
a desire from its Member States for ‘speaking 
with one voice’ at the Special Session through 
the development of a common and coherent 
position. The Netherlands plaid an essential role 
in this process since UNGASS 2016 took place 
during its EU Presidency. This coordinating function 
offered The Netherlands the opportunity to set 
points in the collective discussion agenda, the 
capacity to resolve compromises between 
conflicting points of view from the Member States 
and the possibility to coordinate the dialogue with 
the other global stakeholders.
• On a national level, The Netherlands doesn’t 
have up until this point a systematic mechanism 
for engagement and consultation with CSOs 
concerning drug policy.
Previous Experiences
Prior to the official preparation process towards 
UNGASS 2016, international CSOs advocating for 
Harm Reduction strategies began their preparatory 
processes within the context of events such as the 
8th Civil Society Forum on Drugs 2013 (Brussels), the 
International Drug Policy Reform Conference (Denver) 
and the 11th International Congress on AIDS in Asia 
and Pacific (Bangkok). 
Contextualized within the shifts mentioned above 
in international discussions, these fora offered the 
participating CSOs a possibility to start analyzing 
and concretizing what opportunities for a change 
of direction in drug control policy would exist. In this 
way, CSOs reflected on how to raise the profile of 
their specific concerns and priorities efficiently and 
examined in which way the Harm Reduction and drug 
policy reform sector could be united further. 
As a means towards engaging in these international 
discussions, and aware of the potential impact that 
UNGASS 2016 opens up, CSOs working in the Harm 
Reduction field in The Netherlands activated their 
partnerships with entities such a Harm Reduction 
International and International Drug Policy Consortium.
20
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Expectations
The Dutch government regards UNGASS as an 
opportunity to present its experiences and to try-
and-test interventions on an international context. 
From this perspective, the Netherlands set for itself 
the goal of drawing attention to the importance of 
decriminalizing drug use, the need of guaranteeing 
access to medicine and the impact of approaching 
drug policy from a public health perspective. 
Collaborating with CSO’s, in this case, implies a 
double folded set of expectations:
• To define and articulate the Netherlands position. 
Working with CSO’s allows the Netherlands not 
only to collect the necessary evidence of the 
effectiveness of  harm reduction strategy, but 
also provides it with the information required to 
generate a framework from which to present it;
• To find strategies which effectively articulate 
this position during UNGASS 2016 and to ensure 
that the Netherlands point of view on these 
substantive issues is incorporated into the EU 
common framework.
Development
Considering the global scale of the event, the Ministry 
of Foreign Affairs and the Ministry of Health, Welfare 
and Sports set up an informal consultation network of 
international organizations and national organization 
with a global scope. Critical issues relating to harm 
reduction and human rights are elaborated with 
CSO’s such as the Transnational Institute (TNI), De 
Regenboog Groep/Correlation Network, the TRIMBOS 
Institute,  Aids Foundation East West (AFEW) and 
Mainline, to name a few.
Next to this consultation procedure, for its 
participation at the  58th Session of the CND, the 
Netherlands incorporates CSO’s in its delegation 
in Vienna. With this gesture, CSO’s are granted not 
only the possibility to contribute to the position of 
the delegation during the Session and on its final 
statement, but also to have access to those spaces, 
discussions and information to which otherwise CSO’s 
would not have access to.
Another channel through which the Netherlands 
collaborated with CSO’s was the informal policy 
dialogues facilitated by organizations such as TNI. 
Hold under the Chatham House Rule system, these 
conversations allow its participants to have their 
institutional positions while at the same time are able 
to explore what other positions they could align 
themselves with at UNGASS 2016, to find support 
from other stakeholders and to engage in a cross-
fertilisation process of experiences and best practices 
in drug law reform.
Further, direct and informal approaches initiated by 
both CSOs and the Ministries of Foreign Affairs and 
Health, and articulated via emails and phone calls, 
ensued at several points during the preparatory 
process.
Achievements
In both national and European contributions 
to UNGASS 2016, CSO’s found several of their 
recommendations translated into the official 
statements, despite the fact that harm reduction 
as such is not included in the General Outcome 
document of the UN GA. 
In the Statement submitted by Dutch Delegation on 
the occasion of the UNGASS Segment of the 58th 
CND, presented as well at the UNGASS 2016 Special 
Session, CSO’s saw materialised three main priorities: 
• An evidence-based drug policy that focuses 
first on the public health aspect in which harm 
reduction is one of its key principles;
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• Guaranteeing access to medicine beyond 
and overly strict interpretation of the UN 
Conventions;
• The advocacy of the decriminalisation of drug 
use. 
In the Statement submitted by the EU to the Special 
Session of UNGASS 2016, CSO’s human rights 
approach, condemnation of death penalty, access 
to medicine and harm reduction programs are 
featured. However, the decriminalization of drug use 
was not collected.
Next to this, the decision of including CSO’s in the 
Netherlands CND delegation became a significant 
gesture to other countries that invite to embrace 
a more profound commitment to inclusive and 
open processes. It presented itself as a model for 
meaningful collaboration with CSO’s and rendered 
urgent the contributions put forward by these 
organizations. 
Challenges
During the preparatory process of UNGASS 2016, 
CSO’s that collaborated with the Dutch government 
experienced limitations on the specific topics to 
discuss. As a result, the negotiation or agreements in 
content or employed language were conditioned. 
This fact became relevant considering the 
broader goal of achieving a common EU ground 
and how this orientation affected in return the 
national negotiations. The relationship of the Dutch 
government with the representing delegation at 
CDN in Vienna also experienced such limitations.
Several CSO’s have remarked that the consultation 
platform set by the Netherlands lacked a deep 
level of commitment. This condition was rendered 
visible in how consultations started quite late 
in the process, resulting in a lower capacity to 
dialogue and influence the Dutch position. Next 
to this, it is important to mention a lack of follow-
up meetings in which to assess the development 
of this specific process: the implementation of 
the recommendations and future roadmaps for 
collaboration on drug policy.
Lessons Learned 
The inclusion of CSOs in the preparatory process and 
the government delegations had significant benefits. 
Through a systemic advisory and collaborative 
mechanism and a better understanding of CSO’s 
activities, positions and evidence, the international 
debates gained in specificity and alignment with 
the realities on the ground.
There is still a strong need for more open, transparent 
and inclusive drug policy-making processes. 
Strengthening and empowering a sustained civil 
society participation through cooperative initiatives 
with governments and institutions is vital to achieve 
this goal. 
Global drug policies processes still lack mechanisms 
of accountability to evaluate and respond to its 
inconsistencies. UNGASS 2016  was called to be a 
‘wide-ranging and open debate that considers 
all options’, in which both the preparations and 
the Special Session would take into consideration 
in an open-ended manner the perspectives of 
all stakeholders, members states, UN agencies, 
academia and CSO’s. However, both in the process 
and in the Outcome Document, the UNGASS 
process failed to recognize a multiplicity of these 
views. CSO’s can play a crucial role in monitoring, 
reporting and demanding accountability.
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4.2 An example of the 
importance of CSOs capacities: 
The organisation of shelter 
and social support for people 
experiencing homelessness 
and substance use disorder in 
Amsterdam, Netherlands
Background
As of the 1st of January 2015, the municipal 
administrations in the Netherlands have become 
responsible for the organization of the social support 
for its citizens and for the quality and continuity of 
the services. 
As a result of these decentralization processes, new 
regulations and structures have been developed 
to implement this new legislation. The tasks and 
processes that were previously divided between 
agencies in different levels have now become 
the legal responsibility of the municipalities. An 
integrated service for social support in which public 
health, prevention, care, welfare, housing, and work 
is now the main goal to be attained.
Fostering cooperation and accessibility are 
important values in the development of such a 
system. The municipality of Amsterdam and a wide 
range of stakeholders, service providers and CSO’s 
have been examining together the strategies 
through which to implement these changes in 
policies, as well as  how to improve the already 
existing structures and care programs. 
An example of this cooperation and a result of 
this process is the Housing Program for Vulnerable 
Groups started by the municipality of Amsterdam 
in December 2015. This program is a reform process 
in which housing corporations, health providers, the 
municipality and CSO’s are working together to 
improve the housing situation of vulnerable groups in 
the city.
Previous Experiences 
Shelter and social support for people experiencing 
homelessness and substance disorder in Amsterdam 
find an antecedent in the local social support 
work plan from 2005. One of the main activities 
was the identification of the groups at risk and the 
development of specific and individual care plans. 
Already in this early example, the importance of 
a complete picture of the targeted users of the 
service opened the door for a close collaboration 
with CSO’s.
With the entry into force of the Social Support Act 
of 2007, a new requirement was set to foster active 
participation in the Dutch society through an 
increased responsibility among citizens, institutions 
and CSO’s. From that moment on, the municipalities 
and different stakeholders were expected to 
perform a more extensive supporting role and 
to remove the boundaries that complicate the 
participation of citizens into social life.
One articulation of this framework is the Working 
Plan for support in shelters. Between 2006 and 2014, 
Amsterdam worked together with the Ministry of 
Health, Welfare and Sport, and the municipalities of 
Eindhoven, Rotterdam and Utrecht. 
Building up in the previous multidisciplinary work 
experience, this project emphasized further the 
need for collaboration between all different 
stakeholders and the necessity of focusing on 
individual trajectories for people experiencing 
complex and severe social and health problems. 
A diversity of innovative instruments and policy 
measures are available to achieve these ambitions. 
An example of this is the Self-Reliability Matrix, 
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which proved to be a valuable tool towards a 
comprehensive assessment of the level of self-
reliance of clients and a framework from which to 
coordinate multidisciplinary cooperation. 
Despite the successes of this plan, several pitfalls 
were identified:
• An extensive and overly prolonged consultation 
processes;
• Lack of practical decision making actions;
• Insufficient compliance with the agreements;
• Unclear structures of collaboration between the 
different stakeholders;
• Mutually exclusive differences in the multiplicity 
of regulations and processes.
Objectives & Expectations
The Housing Program for Vulnerable Groups specific 
goal is to offer, within three months, a suitable 
accommodation to those Amsterdam citizens who 
find themselves in an urgent housing need. 
The program relies on three objectives:
• To emphasize individual trajectories over general 
target groups quotas;
• As much as possible have as a starting point the 
independence and self-sufficient of the service’s 
user. Housing and social support are rendered 
transitional towards an independent housing 
situation;
• To look at service user as members of their 
communities. For this, services are strategically 
articulated within the municipality districts.
Development
The Housing Program for Vulnerable Groups 
has been set to run from 2016 until 2018 and its 
development and implementation is carried 
through an integrated approach. Consultation and 
collaboration with all stakeholders (municipality 
departments, public health services, housing 
corporations, care providers, police, CSO’s and 
regional institutions) is central. 
During the first two years, the program has invested 
into forming four lines of action: 
• Developing and improving monitoring and 
control systems;
• Increasing the existing living space available;
• Developing appropriate service arrangements;
• Improving and renewing the current work 
processes.
During 2017, an increment in the available housing 
space has been targeted. Next to this, a new 
draft for an integral approach towards public 
nuisance has been developed and the cooperation 
agreements between all of these agents has been 
further researched and put into practice. The aim is 
to have a completed cooperation agreement by 
2018. 
Achievements
After the Social Support Act of 2015 came into 
force, a transitional period opened that resulted in 
the integration of these policies into the municipal 
realm. The accomplishment of this general goal, and 
in particular of the Housing Program for Vulnerable 
Groups, has been articulated through the creation 
of a decision making, management and workgroup 
structure in which all stakeholders are involved.
Aiming at continuous improvement, regular research 
is carried out. The main bottlenecks have been 
identified and the improvement processes have 
already started. Emphasis has been made in the 
structures by which the intake and re-integration 
flows occur, promoting agility in the services.
Following the Housing First framework, the goal is to 
provide people with suitable housing and guidance 
next to support into participating into society to the 
best of their possibilities. 
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Challenges
Taking into consideration how integral and ambitious 
this project is, the large number of stakeholders 
involved and its different nature (public, private, 
CSO’s), up to date there has been found three 
critical challenges: 
• Coordination of the process between all 
of the stakeholders and the distribution of 
responsibilities and roles;
• Cooperation related to the difficulty of 
reconciling organizational self-interests with a 
broader general framework;
• The large and slow decision processes have 
slowed down the general development of the 
processes involved.
Lessons Learned
• The importance of building upon successful 
practice. CSO’s produce a body of knowledge 
based on practical experience upon which 
successful and efficient services can be 
created.  CSO’s are instrumental in feeding 
these insights into the administrative agencies, 
allowing the work processes and policies to 
align themselves with the reality of the services 
needed;
• CSO’s have been vital in helping vocalizing 
interests, contexts and needs of people in 
vulnerable positions. Acknowledging that no 
partial perspective is conclusive or exclusive 
results in a genuinely integral, client-oriented 
practice;
• An improvement in monitoring the 
implementation of the processes helps greatly 
to create more accurate images of the 
services. CSO’s have proven to be an asset in 
monitoring, assessing and analysing the services 
coordinated by the municipal bodies;
• Social support is not task exclusively related 
to the public domain or public nuisances. 
CSO’s have proven that social support is a 
methodology of work with people at risk or in 
a vulnerable situation. From this position, CSO’s 
deliver valuable technical and analytical 
expertise.
4.3 An example of how CSO 
monitoring and expertise can 
inform drug policy: Mainline & The 
Ministry of Health Welfare & Sports 
in the Netherlands
Background
Established in 1991, Mainline is a harm reduction 
organization that operates on a national and 
international level. Mainline’s mission is to promote 
health and fulfil the human rights of PWUD without a 
primary focus on the reduction of drug use and with 
respect for the individual user’s freedom of choices 
and capabilities.
Within its national team, Mainline works on three 
different lines of action:
• Providing information through its magazine and 
the development of informational material for 
PWUD and professionals in the field or people in 
the network of the user;
• Reaching the groups who are not access by 
regular health care or are still not known to drug 
services;
• Capacity building via trainings, workshops and 
individual instruction and coaching.
In the Netherlands, the Ministry of Health, Welfare 
and Sport coordinates drug policy and works closely 
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with the Ministry of Security and Justice and Foreign 
Affairs. The Ministry of Health has responsibility for 
drug policy in the field of public health, addiction 
prevention and care. 
The Dutch national policy fosters participation of 
PWUD in treatment to prevent their individual and/or 
social situation from worsening. However, whenever 
this is not feasible, support is given to PWUD to 
reduce the harmful consequences of drug use.
For decades, harm reduction has been a central 
feature of Dutch drug policy, aimed at lowering 
drug-induced deaths, drug-related infectious 
diseases, preventing drug-related emergencies as 
well as reducing public nuisances.
In the Netherlands, harm reduction activities are 
implemented through outreach work such as the 
one performed by Mainline in low-threshold facilities 
suchas Drop-In Centers, drug consumption rooms, 
and centres for ‘social addiction care.’ 
Based on its responsibility, the Ministry of Health 
ensures the availability of reliable information and 
stimulates innovation in the field of information, 
prevention and care. It also stimulates research 
and monitoring both for national and international 
purposes.
Within this context, the Ministry of Health funds 
several of the national projects and activities 
carried out by Mainline aimed at harm reduction 
interventions and strategies, outreach work and the 
monitoring of the field with an emphasis in singling 
the development of new drug trends and new 
patterns of consumption.
Previous Experiences
The Ministry of Health has the National Drug Monitor 
as its core system. Its annual publication gives an 
overview of drug use in adults and school-age 
children, addiction treatment demand, drug 
markets and crime. Next to this, it also maintains 
regular contact with Mainline over current 
development.
Until last year, Mainline articulated its monitoring 
function and findings in extensive reports submitted 
twice per year. The information generated during 
its outreach work and the outcomes resulting from 
its multiple projects form the core of the data 
received by the Ministry. For its reports, Mainline 
uses an evidence-based approach when possible, 
addressing the context and PWUD involved, the 
urgency and reach of the phenomenon and, when 
possible, quantitative information.
Starting from 2017 Mainline and the Ministry of Health 
have changed the presentation format into an 
interactive model. The reason for this new approach 
was to ensure that the information presented is 
sufficiently related to the policy developments of 
the Ministry as well as to provide a more precise and 
immediate access to the information, so to better 
translate  it to actual or drafted policies.
Objectives & Goals
Next to the development, implementation and 
advocacy of harm reduction strategies, the 
relationship of the Ministry with Mainline aims at 
the consolidation of high-quality information for 
national and international purposes. Aware that 
drug prevention, treatment and care can only be 
effective if responding to the relevant developments 
in the field, the Ministry of Health relies upon 
organizations and institutions which are categorized 
under the label of “trend watchers”.
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Achievements
Mainline field work and peer involvement strategies 
have proven to be a crucial strategy in streaming 
harm reduction activities and in making social and 
health care accessible to PWUD who cannot (or 
decided not to) seek other institutionalized health 
services.
The support to the harm reductions field and its 
strategies  by the Ministry of Health  has resulted 
in identifying and addressing new drugs and drug 
consumption patterns such a ChemSex, crystal 
meth, Ghb or New Psychoactive Substances 
(NPS). Fruit of the collaboration between Mainline 
and the Ministry of Health, information regarding 
potential health risks has been identified and made 
accessible to other stakeholders.
Mainline’s relationship with the Ministry is up to date 
the longest and more regular CSO’s collaboration 
in drug policy in the Netherlands. In general terms, 
CSO’s involvement in drug policy have been ad 
hoc, lacking transparency and hasnever crystallized 
in a recurrent format. 
Challenges
The frameworks of Mainline and the Ministry of 
Health are not always in alignment. As an activist 
and harm reduction organization, Mainline 
approaches potentially differ from some strategies 
deployed by the Ministry, such as prevention and 
treatment. Considering the project-based nature 
of the funding provided by the government, 
reconciling these agendas when it comes to 
sensitive phenomena may potentially condition the 
way the organization has to structure its activities 
toensure stability. This becomes particularly relevant 
with NPS and other new drugs or patterns when 
compared with a much more commonly agreed 
harm reduction approach towards opiates. 
Taking into consideration the quick evolution of new 
drugs, drug consumption patterns and means of 
distribution, providing quantitative and evidence-
based information it is not always possible. Finding 
a common framework through which to examine 
the urgency and scope of some phenomenon it 
still an unresolved task. Next to this, bridging the 
different speeds, contexts and logics in which drug 
conceptions and institutional work evolves it is not 
always effective as desired.
Lessons Learned
• The implementation of a sustained, systemic and 
transparent collaboration between government 
bodies CSO’s can have a strong impact in the 
production of knowledge about drugs and 
drugs consumption. In return, this affects the 
scope and specificity of drug policies positively;
• CSO’s collaboration with government bodies 
ensures access to social and health care;  
inclusion of PWUD and services via research, 
and the implementation of innovative strategies; 
• The need to generate more inclusive and 
comprehensive frameworks to incorporate the 
diversity of agendas and positions from CSOs 
and governmental bodies as a means towards 
more effective health and care systems.
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5.1 An example of good practice 
of CSI in national drug policy: 
The decision making process in 
Portugal
The emergency of the Portuguese Model on 
Drug Policy, in 2000, became possible due to the 
conjugation of several factors that contributed to a 
particular political and social context of that period:
• The HIV epidemic; 
• The equation Drug=Madness=Death; 
• The media dissemination of the phenomenon; 
• The public disturb and the social fear; 
• The prisons overcrowded (more 75% of inmates 
were condemned for drug related crimes);
• The drug theme as the 1st priority of the 
government.
The Commission for the National Strategy to Fight 
Against Drugs was established in 1998, constituted 
by a pool of experts from different backgrounds 
and fields of intervention (Academics, stakeholders 
from the health and education, researchers, jurists, 
etc.). At the time, the National Strategy integrated 
in a very participatory way the contributions of 
several representatives of the community, namely 
PWUD, their families, school professionals, the health 
structures, the courts, and the neighbourhoods. 
The National Strategy report was brought out in the 
same year and devolved to the Parliament. 
“(…) people working in the Commission were very 
competent in their areas, but also very human. They 
were people very concerned with the relations 
between society and its elements. (…) By the 
conversations I had in the world of the visits that we 
have done, I was very touched about the need to 
change the way of looking at and dealing with the 
issue (Quintanilha, 2014).
In April 1999 the National Strategy was approved, 
stating in the law some fundamental principles, 
among which we highlight three of them:
• The humanist principle;
• The principle of pragmatism, which underlines 
the need for evidence-based innovation;
• The principle of participation, referring the 
participation of community in the definition of 
drug policies and in its further involvement on 
intervention strategies.
5.2 An example of CSO 
cooperation and struggle for 
funding: The organisation of harm 
reduction services in Portugal
As mentioned before, the Portuguese Drug Policy 
Model was partially a product of the dialogue 
established between the State and Civil Society. 
Although in different terms and between different 
actors, that dialogue continued until these 
days. Under that framework, some care services 
(mostly harm reduction responses but also some 
prevention, treatment and reinsertion interventions), 
are provided in local settings by NGOs based on 
an agreement between the State (represented 
by SICAD, the official organism responsible for 
the national action on addictive behaviours and 
dependences) and NGOs. While the state regulates, 
funds and monitors the services, NGOs design and 
implemented them.
5. Portugal 
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Interventions put in place by those means have 
been a product of cooperative relations between 
the State and civil society. For example, in harm 
reduction this has been quite visible along the years 
through the following features: 
• Diagnostics and calls for attribution of funding 
are defined by SICAD based on a participative 
needs assessment which sometimes involves 
local civil society members; 
• Every project dialogues regularly with a local 
interlocutor, who represents SICAD, and with 
whom the communication and cooperation 
process is regularly established; 
• Instruments to collect evaluation data are 
designed by SICAD with the contribution of 
harm reduction teams invited to discuss it in 
open meetings; 
• Intervention guidelines and manuals edited by 
SICAD are also made with the participation of 
those teams; 
• Very frequently, the action of outreach teams 
is put in place with close collaboration of the 
State treatment teams, for example, with nurses 
and medical doctors who go periodically to the 
field.
On the other hand, R3 (the National Harm 
Reduction Network, which includes most of the 
existing projects) has a history of cooperation with 
SICAD. The collaboration happens by inviting R3 
representatives to several scientific/technical events 
and working meetings and by establishing a regular 
pattern of negotiation to improve the performance 
in the field, but also by establishing the working 
and funding conditions. In some moments, this was 
a very productive interaction. This was the case, 
for example, when annual funding was replaced 
by the biennial. In some moments, however, the 
collaboration was not so fruitful.  This is due to the 
fact that SICAD does not have, for instance, a 
Nation Forum for Civil Society organization working 
on drugs field as advisory body. Having that in 
mind, in the present moment, 100% funding (instead 
of 80%) is being discussed in a very informal but 
optimistic atmosphere.
5.3 An example of how CSO 
knowledge and experience foster 
CSI: APDES and the National 
Forum of Civil Society (FNSC) in 
Portugal
In 2010, APDES joined the National Forum of Civil 
Society (FNSC), which is an advisory structure of the 
National Coordination for HIV / AIDS, and since 2017 
(Decree n.º 538-A/2017), also for Tuberculosis and 
Hepatitis. Based on the work that the entities do, the 
FNSC is recognized as a dialogue forum capable of 
giving voice to those affected by and people living 
with HIV / AIDS, promoting the critical participation 
of those involved in all aspects of the response 
to the epidemic. This includes doctors and other 
experts, as well as civil society organizations working 
with children, drug users, sex workers, migrants. 
The objectives of the forum are to ensure the 
contribution to the development, implementation 
and monitoring and evaluation of HIV / AIDS 
policies, as well as to stimulate the networking of 
SC organizations and state structures such as the 
National Program for HIV, TB and Hepatitis. 
In 2011, APDES, in partnership with the Ser + 
association, assumed the secretariat of this 
organization. In 2012, APDES was re-elected for 
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another mandate, this time in partnership with the 
Family Support Group (GAF). In 2013 and 2014, APDES 
continued to assume the functions of secretariat, 
together with GAF. It should be noted that this network 
has been implicated in a series of political actions, 
given the need to show the cost-effectiveness of 
prevention and harm reduction interventions among 
publics of greater vulnerability, taking into account 
the current socioeconomic situation of the country. 
The FNSC is also a privileged space for advocating 
for certain themes, such as: early diagnosis and the 
possibility of using HIV rapid tests in a community 
setting; opening new funding for HIV / AIDS prevention 
in Portugal; harm reduction funding and Needle 
Exchange Programs; and the change of public health 
policies in general, concerning the rights of people 
living with HIV, TB and Hepatitis, among others. 
As a representative of FNSC, APDES has also a seat in 
the Monitoring Commission of the Needle Exchange 
Program. On September 20, 2016, the III National 
Meeting of the National Civil Society Forum for HIV / 
AIDS was held, at which Guarda Prisional Prevention 
project, based on peer education for health 
promotion, was presented. 
The Needle Exchange Program “Say No to a Second 
Hand Syringe” provides the free supply of injection 
material for consumption, avoiding the sharing of 
needles, syringes and other materials among users 
and allowing the collection of used syringes. The 
Program covers the 18 districts of the national territory 
and the autonomous regions of the Azores and 
Madeira. Since 2012, the Needle Exchange Program is 
monitored by the National HIV / AIDS, TB and Hepatitis 
Program, assisted by this Monitoring Committee. 
Currently, the program is provided through the 
national network of community pharmacies, harm 
reduction teams and primary health care units, mobile 
clinic and a few state structures identifying lack of 
materials and monitoring all types of services delivery 
of the needle exchange Kits. APDES also collaborates 
in the distribution of the Kits through the outreach 
teams Giru Gaia, GiruBarcelos and GiruSetúbal. 
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6.1. An example for active 
participation: CS involvement in 
national drug policy in Slovenia
Year(s) of implementation: 2018
Level of the action: National
Actions by policy makers: implementation of 
dialogue mechanism
Actions by CSOs:building coalitions, (media) 
advocacy actions
Stakeholders and parties involved: Commission 
on Drugs of the Government of Slovenia, 
Ministry of Health, CNVOS (national NGO 
umbrella network), CSOs in the field of 
prevention among others. 
Background
In 2000, the Commission on Drugs of the 
Government of Slovenia was established by law, 
with the task of being responsible for drug policy at 
the inter-ministerial level. The Commission consists of 
representatives of nine responsible ministries:health, 
internal affairs, labour, family and social affairs, 
education, interior, justice, finance, agriculture, 
defence and foreign affairs, and additionally of 
two representatives of CSOs. Due to very limited 
possibilities for CSOs in the field of prevention to be 
involved in the work of the Commission, an extension 
was proposed by a group/network of CSOs in the 
field of prevention. Some of the proponents were, 
for instance, the Prevention Platform, Red Cross 
Slovenia, Slovenian Coalition for Health, Environment 
and Tobacco Control, Network 25x25 and Youth 
Association No Excuse Slovenia. The action is still 
ongoing.
The Commission on Drugs of the Government of 
Slovenia (Commission) is an inter-ministerial body 
in charge of coordinating the policies, measures, 
and programmes adopted by the Government 
of the Republic of Slovenia. As regards the 
Resolution on the National Programme in the 
Field of Illicit Drugs 2014-2020, the Commission 
monitors the implementation of the strategy and 
action plans and coordinates policies between 
individual ministries. The Commission promotes and 
coordinates the government policy, measures, and 
programmes for reducing the supply and demand 
for illicit drugs, reducing the harm from illicit drug use, 
treatment, and social rehabilitation. It is composed 
of representatives of all ministries that are indirectly 
or directly associated with the drug problem. Two 
members of the Commission are representatives of 
non-governmental organizations, but none of them 
is from the prevention field, something the national 
action wishes to change. 
Ministries and other public authorities implement 
measures coordinated at the inter-ministerial 
level in their respective areas, provide funds for its 
operation, and coordinate their activities with other 
ministries through the Commission. Each ministry 
assumes responsibility for the implementation 
of their part of the Resolution on the National 
Programme in the Field of Illicit Drugs 2014-2020. The 
ministries responsible for the implementation of the 
National Programme are the Ministry of Health, the 
Ministry of Labour, Family, Social Affairs and Equal 
Opportunities, the Ministry of the Interior, the Ministry 
6 Slovenia
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of Agriculture, the Ministry of Education, Science 
and Sport, the Ministry of Justice, the Ministry of 
Defence, the Ministry of Foreign Affairs, and the 
Ministry of Finance.
The Ministry of Health is responsible for coordination 
in the field of drugs and monitoring the issue of 
reducing the supply and demand for illicit drugs, 
reducing the harm from illicit drug use, and the issue 
of treating and addressing social issues associated 
with illicit drug use. That is why the national action 
addresses the Ministry of Health, although this 
Ministry is  reluctant to change the regulation and 
composition of the Commission. More efforts are 
needed to discuss this issue and some other levels 
could be used to overcome the problem with the 
Ministry of Health. This could be done, for instance, 
by addressing the issue with the  Government as a 
whole and the Parliament and with political parties 
in the parliament.
Additionally, an inter-ministerial working group has 
been established for the operational monitoring 
of the implementation of the Resolution on the 
National Programme in the Illicit Field of Drugs. The 
members of this working group are representatives 
of the ministries and the information unit, as well as 
of researchers, NGOs, and local action groups. Here, 
however, there is a similar problem  as the one with 
the Commission: no representative of CSOs in the 
field of prevention is involved in the work of this inter-
ministerial working group.
With the help of several CSOs in the field of 
prevention, the national action plan will continue 
to better involve prevention CSOs in policy- and 
decision-making processes. The intention is to 
involve people who use drugs as well, as they are 
also misrepresented in the above mentioned drug 
policy bodies in Slovenia. The final aims is to reframe 
the whole system of civil society involvement, 
for instance, the national drug strategy, national 
action plans, working groups, and commissions. 
The core set of activities will be implemented in the 
spring of 2018 and, since Slovenia is preparing for 
parliamentary elections in June 2018, we hope for 
improvement. 
Main objectives and expectations
To extend the membership of the Commission to 
representatives of CSOs in the field of prevention, 
since, at the moment, they are excluded from 
policy- and decision-making processes (including 
information, consultation, policy dialog and 
partnership)
Achievements /positive changes
This is still an ongoing process)
Challenges
Negative position of the Ministry of Health:  
don’t want to change the regulation and allow  
the extension of the Commission.
Still an ongoing process.
Lessons learned
Advocating for change at higher levels, such as 
government and parliament, political parties and 
important individuals in politics, is needed but not 
always sustainable. It is very likely that we have to 
wait for the new elections in June 2018 and repeat 
advocacy action w
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